|
Aug 12
|
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
|
|
Aug 11
|
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
|
|
Aug 11
|
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
|
|
Aug 6
|
Veru Announces Reverse Stock Split
|
|
Aug 5
|
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
|
|
Jul 22
|
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
|
|
Jun 26
|
Veru And Two Other Penny Stocks To Consider
|
|
Feb 20
|
3 US Penny Stocks With Market Caps Under $300M To Consider
|
|
Feb 14
|
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...
|
|
Feb 13
|
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
|
|
Dec 31
|
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline
|
|
Dec 31
|
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
|